Navigation Links
Aquavit Pharmaceuticals and U-Bio Med Enter Exclusive Worldwide License Agreement for Microneedle Technology (AQT-001)
Date:7/18/2013

NEW YORK, July 18, 2013 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. announces it has signed a definitive licensing agreement with U-Bio Med Inc., a medical technology device company in South Korea, for the worldwide commercialization of the company's microneedle device technology. 

The definitive agreement, signed on July 14, 2013, provides Aquavit Pharmaceuticals a perpetual exclusive right to license, sub-license, improve and/or commercialize the patented microneedle technology and all of its derivatives.  The companies have not disclosed the deal amount.

"Dr. Eum is an exceptional scientist. The technology will accelerate our consorted development towards disruptive innovation in drug delivery," said Sobin Chang, Aquavit's Chief Executive Officer.

Aquavit will own all intellectual property pertaining to further development of Aquavit's pipeline products.  The company has begun the registration process with the FDA and CE for specialized use.

"In addition to the patented delivery mechanism of the needles, we are using pure gold to ensure quality and safety," said Dr. Nyun-Sik Eum, CEO of U-Bio Med.

AQT-001 has been FDA registered and will be commercially available in US and globally shortly.  The technology will address the unmet needs of the 11 billion dollar medical aesthetics market and the 30 billion dollar vitamin and mineral market.

"It is an innovative delivery system for botulinum toxins and dermal fillers.  I use it with Botox, hyaluronic acid-based fillers and vitamin combinations," said Dr. David Shafer, Chief Medical Technology Officer.

About U-Bio Med Inc.

U-Bio Med (Ubiquitous Bio Medical Equipment) is a Korean company that specializes in the development and manufacturing of precise test equipment, bio-sensor based optical systems and practical medical devices.  

About Aquavit Pharmaceuticals, Inc.

Aquavit Pharmaceuticals is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, medical device, and health technologies. For more information, visit www.aquavitpharma.com or contact Anne Hargreaves at 212-210-9272.


'/>"/>
SOURCE Aquavit Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aquavit and Green Cross Sign Strategic Collaboration MOU on IBX-001 Product Development and Commercialization in Asia
2. Aquavit Pharmaceuticals forms Alliance Partnership with Accelrys
3. Aquavit Pharmaceuticals Inc. Appoints David Shafer, MD., FACS., New Chief Medical Technology Officer
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/4/2017)... 4, 2017  Fortuna Fix Inc. (" Fortuna "), ... first to eliminate the need for embryonic and fetal stem ... neurodegenerative diseases. Fortuna announced today the ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald , ... and Professor James Giordano , PhD. "We ...
Breaking Medicine Technology:
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. Genie ... are thrilled to partner with Cupron® to provide customers with a game changing ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Rob Lowe acts ... upcoming production of the series is on hiking in American. Viewers can reconnect with ... the great benefits of hiking. , Many consumers have looked for an inventive new ...
(Date:5/26/2017)... ... ... “Just What Happened in the Garden of Eden”: retells the stories of three Bible figures ... of published author, Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. ... three. At six, they moved to Dayton, Ohio, where Penny graduated high school. ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board ... He is known for his distinguished expertise and experience in the diagnosis and treatment ... training in treating renovascular disease and aortic aneurysm . He is known for ...
Breaking Medicine News(10 mins):